The global life sciences innovation ecosystem is gaining a powerful new engine with the launch of DIA ASCENT and the LIFT program, designed to accelerate early-stage biotechnology companies and bridge longstanding gaps between scientific discovery, investment, and product development. Announced on January 21, 2026, by the Drug Information Association (DIA), these initiatives aim to provide emerging biotech founders with education, connections, regulatory insights, investor access, and strategic support at every stage of the innovation pathway — transforming how next-generation therapies and technologies move from concept to global impact.
The ASCENT platform represents a new global framework by DIA to support early-stage innovators in the life sciences interested in drug development, diagnostics, digital health, and other breakthrough domains. Historically, biotech startups face persistent challenges: limited access to knowledgeable investors who understand complex science, fragmented expertise across regulatory pathways, and a lack of structured programs that prepare teams for real-world execution and commercialization. ASCENT seeks to fill this critical gap by creating a structured, multi-stage pathway that includes curated education, mentorship from industry leaders, regulatory insights, and global visibility within the broader life sciences community.
Central to ASCENT’s early rollout is the LIFT Series (Linking Innovation, Funding, and Translation), a three-phase initiative designed to integrate emerging companies with the global biotech innovation ecosystem. Launching in early 2026, the LIFT Series begins with a virtual masterclass program scheduled for February, featuring expert-led sessions on key competencies such as fund-raising strategies, clinical development planning, regulatory pathways, financial modelling, and even the role of artificial intelligence in drug development. These sessions are aimed at equipping founders with practical knowledge and frameworks to navigate the complex early-stage landscape with confidence.
The second phase sees LIFT programming integrated into DIA Europe 2026, taking place in Rotterdam, Netherlands from March 24–26, where dedicated biotech and startup tracks are embedded within a major global meeting of over 2,500 professionals. Here, startups can engage directly with investors, regulators, and industry experts, participate in live pitch competitions, and join curated networking opportunities that could catalyse investment and strategic partnerships. Events like regulator and investor roundtables are designed not only to educate but also to connect innovators with decision-makers who can move projects forward.
The third and culminating phase of the LIFT Series will occur at the DIA 2026 Global Annual Meeting in Philadelphia, Pennsylvania from June 14–18, 2026. This larger global forum’s expanded LIFT programming includes a Startup Row, two targeted pitch events focused on drug and therapy development, and broader networking opportunities that bring the full force of the life sciences ecosystem together — from pharma leadership and biotech founders to funding partners and regulatory specialists. This convergence highlights DIA’s intent to make ASCENT and LIFT core pillars of early-stage biotech acceleration going forward.
Marwan Fathallah, CEO of DIA, emphasised the mission behind the initiative, noting that the organisation’s long history of convening stakeholders in the drug, device, and diagnostic sectors now extends to supporting innovators at the earliest stages of creation. By doing so, DIA hopes to strengthen the global life sciences pipeline, reduce innovation bottlenecks, and ensure that promising science has a clear pathway to reach patients — a foundational goal for accelerating public health advances.
Industry experts say ASCENT and the LIFT Series could become game-changers for biotech startups — eliminating traditional barriers like disjointed regulatory guidance, limited investor access, and the absence of structured mentoring. By bringing educational masterclasses, pitch opportunities, and investor-ready programming under one umbrella, the initiative aligns technical science with business acumen, which is essential for translating ideas into viable products.
Furthermore, there is growing interest in initiatives that blend scientific expertise with commercial readiness, as biotech founders often struggle with strategic growth alongside research challenges. Programs like LIFT provide a critical forum where founders can receive real-time feedback on regulatory strategy, clinical development plans, and fundraising approaches — knowledge that historically required years of experience or expensive consulting.
The launch of DIA ASCENT and the LIFT Series underlines a broader trend in life sciences toward collaborative innovation ecosystems, where nonprofits, regulators, investors, and entrepreneurs work together to accelerate breakthroughs and deliver new therapeutic options faster. With virtual training already open for registration and major global events lined up, 2026 could be a defining year for early-stage biotech development — one where ASCENT and LIFT help reshape how innovation journeys begin, grow, and succeed on the world stage.
